We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Fastnet Equity | LSE:FAST | London | Ordinary Share | GB00B85HRF56 | ORD 3.8P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.975 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
22/2/2016 11:34 | The cynic in me is assuming the price for the new shares would probably be at a discount to the suspension price....and that existing shareholders don't get a look in..... | eburne1960 | |
22/2/2016 11:27 | No point in guessing and surmising. Just wait for the admissions prospectus to be issued. Though I can't imagine the £20m to be raised (according to Irish Independent & Sunday Times reports) will at a price less than the 4p that Cathal paid last summer. | papillon | |
22/2/2016 11:26 | bigwavedave - the £20m will be raised by issuing new shares. Therefore, if the shares are issued at the market price at suspension, then the total market cap will be c.£30m at the suspension price. Thus, if Jacksonpillock's view is right, then the market cap when it relists will be £100m+.....you decide if that's realistic.... | eburne1960 | |
22/2/2016 11:14 | One thing is for sure. When this baby relists, it will be many multiples of where it is today. I may have become a bit disillusioned over the last few months, not that anyone would have noticed, at the perceived lack of progress here, but I'm big enough to eat my own words and admit when I'm wrong. If everything goes to plan here this is going to go balistc. Great cash position and very, very advanced talks and investments very advanced as well as being recognised and approved by the EU regulator. I advise all to look at the websites of the two companies amryt and fastnet will take over if this deal goes through. | jacksonpollack | |
22/2/2016 10:28 | Yes, agreed. I guess we need more detail before we can come up with serious valuations. | bigwavedave | |
22/2/2016 09:53 | Market caps aren't everything, especially on aim shares. What will increase the share price significantly is a combination of the market cap, bod members and investments. Fastnet seems to have all three in their hands. Good times ahead. | jacksonpollack | |
22/2/2016 09:44 | FAST market cap is £9.8m. If the Sunday Times article is correct, and Amryt raises £20m, that will give the combined entity a market cap of £30m-ish. Will that translate into a share price of 3x current ie circa 9p? Maybe it is not as simple as that. I haven't been in this situation before, so not sure about how RTA will work in terms of share value. | bigwavedave | |
22/2/2016 09:39 | I knew through the previous RNS's that fastnet wanted in on developing pharma's but I didn't realise how far advanced they were aiming for. Just look at the companies that come with this deal. Looks like the cove touch is coming here. | jacksonpollack | |
22/2/2016 09:14 | "Amryt has signed conditional deals to buy two companies - Som Pharmaceuticals and Birken - which will complete if the reverse takeover goes ahead" Here are the 2 companies....very exciting times for us that kept the faith. hxxp://www.birken.eu hxxp://www.sompharma | karlm | |
22/2/2016 08:43 | A shell bringing 20 million and aquiring 2 companies very interesting | risk1 | |
22/2/2016 08:36 | The stigologist. All companies are shells until they make their first investment. Buying another shell is not uncommon. I think fastnet are acquiring more than just a shell company. Especially if the company has a EU registered drug attached to it. And bods with a proven track record. Amryt has signed conditional deals to buy two companies - Som Pharmaceuticals and Birken - which will complete if the reverse takeover goes ahead. Amryt would then have a product, approved by the European regulator, which will be developed as a treatment for epidermolysis bullosa (EB), a genetic skin disease that causes painful blisters to form as a result of the slightest friction. Going public will enable the company to scale more quickly. The disease was the subject of a well-known Channel 4 documentary entitled The Boy Whose Skin Fell Off. | jacksonpollack | |
22/2/2016 08:31 | deckav. You couldn't be more wrong | jacksonpollack | |
22/2/2016 08:27 | JP. Strange that....I thought Cathal was only there to pocket wages each month. | deckav | |
22/2/2016 08:24 | It's not even a proper company by the looks of it. A shell buying a shell. | the stigologist | |
22/2/2016 08:06 | I don't expect a drawn out wait here, reading through the RNS it sounds as though negotiations have been going on for some time. Must be quite strange negotiating with yourself, cathal being on both bods, lol. | jacksonpollack | |
22/2/2016 07:58 | And now we wait... | alphabravo321 | |
22/2/2016 07:42 | Guys, fill your boots in New World Oil and Gas , an aim cash-shell trading at cash . Adam Reynolds is now on the BOD and has a formidable track-record . There are rumours he is going to inject a pharmaceuticals company into it . Do your own research . Well worth a look . | talkman2 | |
22/2/2016 07:34 | And there we have it RNS released. Two RNS to be precise. Think cathal was having a bit of fun with us in issuing it slightly after 7am, lol. | jacksonpollack | |
22/2/2016 07:34 | Suspenders | risk1 | |
22/2/2016 07:28 | richpassi. It could go either way today. If pi's take the stories at face value the share price could rocket up. But with no RNS to back them up it could just as easily fall back. I'm more than a little surprised an RNS hasn't arrived. Fastnet would have been aware of the story as any reporter with his salt would have given fastnet the heads up about its imminent release. | jacksonpollack | |
22/2/2016 07:21 | JP you make me laugh 😀 | risk1 | |
22/2/2016 07:19 | Well well, very strange. Fully expected 7am RNS. Could it be the papers have jumped the gun and their sources have identified the wrong company? I hope not and it would be hard to look beyond fastnet in this deal as the bod names all tie in together nicely. I can't see cathal letting another company in on this deal when fastnet are ready and waiting and he sits on both bods. | jacksonpollack | |
22/2/2016 07:10 | i know its only 7.05 but I did expect a 7am rns, if .......if it doesn't come before 8 could be very interesting ! so if it stays quiet and we just sitting here how about playing 'what price do I expect price to be suspended at'....if no rns before 8am , im going for 4.25 :) | richpassi |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions